Scientific Frontline: Extended "At a Glance" Summary: Urine-Derived Stem Cell Liver Model for Alpha-1-Antitrypsin Deficiency
The Core Concept: Researchers at Heinrich Heine University Düsseldorf (HHU) and University Hospital Düsseldorf (UKD) developed a patient-specific liver model for alpha-1-antitrypsin deficiency (AATD) using hepatocyte-like cells (HLCs) differentiated from induced pluripotent stem cells (iPSCs). The cellular model accurately replicates the intracellular accumulation of misfolded alpha-1-antitrypsin (AAT) protein, enabling laboratory testing of candidate therapies for this rare genetic metabolic disorder.
Key Distinction/Mechanism: Unlike most established cell reprogramming methods that require invasive tissue collection, the team generated iPSCs from patient urine—a noninvasive source readily available from children and severely ill individuals—before differentiating them into liver cells (hepatocytes). In AATD, a genetic mutation causes hepatocytes to produce misfolded AAT that fails to secrete properly into blood plasma, leaving lung tissue vulnerable to inflammatory enzymes while toxic protein aggregates build up inside the liver. When researchers tested four therapeutic candidates in this model, two established drugs—suberoylanilide hydroxamic acid (SAHA) and carbamazepine—reduced intracellular AAT accumulation, with transcriptome analyses showing that SAHA increased the expression of chaperone proteins that assist protein folding.
Major Frameworks/Components:
- Urine-Derived Induced Pluripotent Stem Cells (iPSCs): Reprogramming cells isolated noninvasively from patient urine yields pluripotent stem cells that can be differentiated into hepatocyte-like cells reproducing the cellular pathology of AATD.
- Alpha-1-Antitrypsin (AAT) Protein Misfolding: A genetic mutation prevents hepatocytes from properly folding and secreting AAT, causing both inflammatory lung damage and hepatic protein accumulation that elevates the risk of cellular stress, cirrhosis, and liver tumors.
- Drug Repurposing and Chaperone Upregulation: Screening four compounds demonstrated that the cancer therapy SAHA and the antiepileptic drug carbamazepine lower intracellular AAT levels, with SAHA acting at least in part by upregulating folding-assisting chaperone proteins.
Branches of Science: Stem Cell Biology, Hepatology, Pharmacology, and Medical Genetics.
Future Application: Researchers plan to use this patient-specific liver model to screen and identify new therapeutic agents targeting AATD. The collaborative team is also preparing a follow-up study to refine the model's applications and better characterize disease progression and liver involvement in younger patients.
Why It Matters: A scarcity of accurate liver models has long impeded the development of targeted treatments for AATD, leaving many patients with severe hepatic involvement reliant on liver transplantation. Generating iPSCs noninvasively from urine expands access to patient-specific disease modeling across vulnerable populations, including children. Demonstrating that clinically established drugs such as SAHA and carbamazepine can mitigate toxic protein buildup also supports drug repurposing as a practical avenue toward future therapies.
Researchers from Heinrich Heine University Düsseldorf (HHU) have developed a model to facilitate research into the effects of alpha-1-antitrypsin deficiency (AATD) on the liver. According to the study findings, the model—based on induced pluripotent stem cells (iPSCs)—reproduces key cellular hallmarks of AATD-associated liver pathology in vitro, including the intracellular accumulation of misfolded Z-alpha-1-antitrypsin (Z-AAT) polymers. The platform expands the limited set of human in vitro models available for studying AATD-related liver pathology and screening candidate compounds in preclinical research. The researchers published their findings in the scientific journal Stem Cell Research & Therapy.
AATD is a rare inherited disorder affecting the liver and lungs. Mutations in the SERPINA1 gene—most commonly the Z allele—cause liver cells (hepatocytes) to produce misfolded alpha-1-antitrypsin (AAT), reducing its secretion into the bloodstream. AAT plays an important role in regulating inflammatory processes in the body by mitigating excessive reactions that lead to tissue damage.
When circulating AAT levels are insufficient, uninhibited inflammatory proteases—primarily neutrophil elastase—degrade healthy tissue. This tissue degradation predominantly affects the lungs and results in severe symptoms, such as coughing, shortness of breath, or airway constriction. In some patients, liver function is also impaired because misfolded AAT polymers accumulate in hepatocytes, triggering cellular stress. Affected patients face a substantially elevated risk of developing cirrhosis and liver cancer (hepatocellular carcinoma). Although several experimental therapies are under investigation, liver transplantation remains the only curative option for patients who progress to severe, end-stage liver disease.
Research into potential new therapies is impeded by the scarcity of models for an AATD-affected liver. A team from the Institute of Stem Cell Research and Regenerative Medicine at HHU and University Hospital Düsseldorf, directed by Professor James Adjaye, has therefore developed a model to facilitate future research. First, the team reprogrammed cells derived from two patients (n = 2) into iPSCs—a small donor cohort that limits generalizability across the variable clinical spectrum of AATD—which can differentiate into multiple cell types in the laboratory. Unlike most established cell sources for such reprogramming, the Düsseldorf researchers isolated cells shed in urine as the starting material—a noninvasive source obtainable even from children or severely ill patients. The researchers then differentiated the iPSCs into hepatocyte-like cells (HLCs).
In the next phase of the study, the team assessed whether these HLCs could be used to test candidate therapies for AATD. The researchers evaluated four compounds for their effects on intracellular AAT accumulation; two—suberoylanilide hydroxamic acid (SAHA) and carbamazepine—reduced accumulated AAT in the cells, whereas the other two did not demonstrate this effect. Both active compounds are established drugs approved for other indications and have previously been studied as repurposing candidates: SAHA (clinically known as vorinostat) is a histone deacetylase inhibitor approved to treat cutaneous T-cell lymphoma, whereas carbamazepine is an anticonvulsant prescribed for focal epilepsy and related neurological conditions. Transcriptome analyses also showed increased expression of genes encoding molecular chaperones during SAHA treatment. Because chaperones assist protein folding, this mRNA-level upregulation represents a plausible—though not yet conclusively proven—mechanism for reduced AAT accumulation. As these experiments were conducted entirely in vitro, the findings demonstrate model responsiveness rather than clinical efficacy or safety in patients.
“We were able to demonstrate that our model is suitable for studying AATD and its therapy further,” said lead author Dr. Nina Graffmann of the Institute of Stem Cell Research and Regenerative Medicine at University Hospital Düsseldorf. Graffmann added that the platform could help researchers investigate candidate therapies and clarify how AATD progresses—including potential liver involvement—in younger patients.
The study was conducted in collaboration with Dr. Malin Fromme and Professor Pavel Strnad of University Hospital RWTH Aachen, the Medical University Lausitz–Carl Thiem (MUL-CT) in Cottbus, and the Alpha1 Liver Center of Alpha1 Germany, the German patient organization for alpha-1-antitrypsin deficiency. The collaborating institutions plan a follow-up study to further evaluate the applications and performance of the iPSC-derived liver model.
Funding: Open Access funding enabled and organized by Projekt DEAL. J.A. acknowledges funding from the Medical Faculty of Heinrich-Heine University Düsseldorf, C.L. and N.G. were funded by the Else Kroener-Fresenius Foundation – 2020_EKEA.64. N.G. acknowledges funding from the Ministry for Culture and Sciences North Rhine Westfalia – 005-2305-0038.
Published in journal: Stem Cell Research & Therapy
Authors: Nina Graffmann, Rabea Hokamp, Christiane Lörch, Malin Fromme, Wasco Wruck, Pavel Strnad, and James Adjaye
Source/Credit: Heinrich Heine University Düsseldorf
Edited by: Scientific Frontline
Reference Number: cbio112126_01
